Bausch Health Companies (BHC) PT Raised to $18.00 at JPMorgan Chase & Co.

Bausch Health Companies (NYSE:BHC) had its price objective upped by JPMorgan Chase & Co. to $18.00 in a report issued on Wednesday morning, The Fly reports. JPMorgan Chase & Co. currently has an underweight rating on the stock.

A number of other equities analysts also recently commented on the company. Piper Jaffray Companies set a $16.00 price target on Bausch Health Companies and gave the stock a sell rating in a research note on Tuesday, August 7th. Cantor Fitzgerald reiterated a buy rating and issued a $32.00 price target on shares of Bausch Health Companies in a research note on Tuesday, August 7th. Mizuho reiterated a buy rating and issued a $31.00 price target on shares of Bausch Health Companies in a research note on Tuesday, August 7th. Finally, Wells Fargo & Co reiterated a sell rating on shares of Bausch Health Companies in a research note on Monday, August 6th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $24.60.

Bausch Health Companies opened at $21.85 on Wednesday, Marketbeat reports. The stock has a market capitalization of $8.08 billion, a P/E ratio of 6.03, a PEG ratio of 0.33 and a beta of -0.50. Bausch Health Companies has a one year low of $10.94 and a one year high of $27.79. The company has a debt-to-equity ratio of 6.99, a current ratio of 1.14 and a quick ratio of 0.92.

Bausch Health Companies (NYSE:BHC) last posted its quarterly earnings results on Tuesday, August 7th. The company reported $0.93 EPS for the quarter, topping the Zacks’ consensus estimate of $0.81 by $0.12. The business had revenue of $2.13 billion during the quarter, compared to the consensus estimate of $2.05 billion. Bausch Health Companies had a positive return on equity of 27.83% and a negative net margin of 20.60%. analysts predict that Bausch Health Companies will post 3.51 EPS for the current year.

A number of large investors have recently bought and sold shares of BHC. Point View Wealth Management Inc. acquired a new position in Bausch Health Companies in the second quarter worth about $1,132,000. Tobam bought a new position in Bausch Health Companies in the second quarter worth about $13,886,000. Finally, Private Management Group Inc. bought a new position in Bausch Health Companies in the second quarter worth about $28,474,000. Institutional investors and hedge funds own 47.20% of the company’s stock.

Bausch Health Companies Company Profile

There is no company description available for Bausch Health Companies Inc

Read More: Short Selling Stocks and Day Traders

The Fly

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply